Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 6/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CASP6 | P55212 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11784426 | 0.98 | GSR (0.50) | GSRMEN1KMT2ACA2CA1 | |
| SCHEMBL27256050 | 0.98 | GSR (0.50) | GSRMEN1KMT2ACA2CA1 | |
| SCHEMBL11881043 | 0.98 | GSR (0.50) | GSRMEN1KMT2ACA2CA1 | |
| SCHEMBL15494525 | 0.84 | — | — | |
| SCHEMBL9323765 | 0.81 | GSR (0.36) | GSRCASP6 | |
| Nitric Acid SCHEMBL9803591 | 0.76 | GSR (0.54) | GSRMEN1KMT2ACA2CA1 | |
| Nitric Acid SCHEMBL9874582 | 0.76 | GSR (0.54) | GSRMEN1KMT2ACA2CA1 | |
| SCHEMBL13322803 | 0.74 | GSR (0.36) | GSR | |
| SCHEMBL16254272 | 0.72 | GSR (0.45) | GSRMEN1KMT2ACA2CA1 | |
| SCHEMBL19551024 | 0.72 | GSR (0.45) | GSRMEN1KMT2ACA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115677714-B | Intermediate in preparation of (+) -water podocarpine and application thereof | 昆明医科大学 | 2024-06-11 | — | — | CN | disclosed |
| CN-115894507-B | Synthesis method and application of (+) -water podocarpine | 昆明医科大学 | 2024-06-07 | — | — | CN | disclosed |
| CN-115894507-A | Method for synthesizing (+) -canna oensis alkali and application thereof | 昆明医科大学 | 2023-04-04 | — | — | CN | disclosed |
| CN-115677714-A | Intermediate in preparation of (+) -coprinus comatus alkali and application thereof | 昆明医科大学 | 2023-02-03 | — | — | CN | disclosed |
| EP-2563765-B1 | BICYCLIC COMPOUND DERIVATIVES AND THEIR USE AS ACC INHIBITORS. | TAKEDA PHARMACEUTICAL (JP) | 2015-05-27 | — | — | EP | disclosed |
| US-8703758-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-04-22 | — | — | US | disclosed |
| US-8703758-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-04-22 | — | — | US | disclosed |
| US-20110263562-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-10-27 | — | — | US | disclosed |
| US-20110263562-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-10-27 | — | — | US | disclosed |
| CN-1190390-A | Nitric oxide synthase inhibitors derived from cyclic amidines | SEARLE & CO (US) | 1998-08-12 | — | — | CN | disclosed |
| EP-0824523-A1 | NITRIC OXIDE SYNTHASE INHIBITORS DERIVED FROM CYCLIC AMIDINES | G.D. Searle & Co. (US) | 1998-02-25 | — | — | EP | disclosed |
| WO-1996035677-A1 | NITRIC OXIDE SYNTHASE INHIBITORS DERIVED FROM CYCLIC AMIDINES | G.D. SEARLE & CO. (US) | 1996-11-14 | — | — | WO | disclosed |
| EP-0083332-A2 | Asymmetric reduction of nitro-containing prochiral compounds | MONSANTO COMPANY (US) | 1983-07-06 | — | — | EP | disclosed |
| US-3950385-A | Preparation of nitronitrates | TEXACO INC. (US) | 1976-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263562-A1 | BICYCLIC COMPOUND | ACACA, CPT1B, ACACB | GSR 1075/4885MEN1 2882/4885KMT2A 2195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.